Abstract

The Contractor shall develop a Phase I protocol design to evaluate the combination of an anti-GD3 antibody and either a biologic, such as recombinant and/or natural interferon, or cytoreductive agent in patients with melanoma.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM047665-002004
Application #
3612088
Study Section
Project Start
1987-06-30
Project End
Budget Start
1989-09-30
Budget End
1990-06-30
Support Year
Fiscal Year
1989
Total Cost
Indirect Cost

  Institution

Name
Memorial Hospital for Cancer & Allied Di
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10021